Experimental Biology 2004
          (AAA, AAI, APS, ASIP, ASNS, ASPET)

    Saturday April 17-Wednesday April 21, 2004
                            Washington, DC

         Late-breaking Abstract Deadline:  February 25, 2004

Posters will be presented daily from 12:30 pm - 2:45 pm in Hall AB

Symposia

Sunday Morning (9:30 am - 12:00 noon)

Pharmacology of eating & energy utilization:  Neurocircuitry & effectors
Chairs:  Timothy H. Moran & Kenny J. Simansky

Regulation of eating by gastrointestinal hormone signals to the brain
  Stephen R. Bloom, Imperial College Faculty of Med., London, U.K.

Central neural transduction of peripheral signals regulating food intake and energy balance: synaptic physiology of the medial hypothalamus
  Michael A. Cowley, Oregon Health & Science Univ.

How peripheral endocrine signals of metabolic status influence motivational systems in the brain: Insulin, leptin, dopamine and reward
  Dianne F. Lattemann, VA Pugent Sound Hlth Care System & Univ. of Washington

Relationship between opioidergic stimulation of eating and G-protein coupling in the reward circuitry
  Heather Frost, Drexel Univ. Col. of Med.

From metabolic fluctuation to network action: How glucosensing neurons modulate eating
Barry E. Levin, VA Med. Ctr., East Orange, NJ

Electronic resources for pharmacology education
Chairs:  Gary Rosenfeld & Jack Strandhoy

Introduction and the use of web based Knowledge Objectives to enhance teaching and learning in pharmacology
  Gary C. Rosenfeld, Univ. of Texas Hlth. Sci. Ctr., Houston

Web Based database reference works in teaching graduate pharmacology
  David B. Bylund, Univ. of Nebraska Med. Ctr. 

HEAL and BEN as mulitmedia database resources for medical education
  Robert G. Carroll, East Carolina Univ.

Using computer and PDA resources to enhance pharmacology education
  Jack W. Strandhoy, Wake Forest Univ. Sch. of Med.

Mechanisms of adverse drug reactions
Chair:  Ronald N. Hines

Reactive intermediates as underlying causes of adverse drug reactions
  B. Kevin Park, Univ. of Liverpool Med. Sch., U.K.

Felbamate as a model for understanding idiosyncratic drug reactions
  Christine M. Dieckhaus, Merck Res. Labs

Potential role of cytochrome b5 and cytochrome b5 reductase in drug hypersensitivity
  Sunil Bajad, Univ. of Wisconsin at Madison.

Pharmacogenomics as a tool to better understand adverse drug reactions
  Dan M. Roden, Vanderbilt Univ. Sch. of Med.

Genetic variants of CYP2C9 as risk factors for coumadin-induced adverse drug reactions
  Allan E. Rettie, Univ. of Washington Sch. of Pharmacy

Toxicological & health implications of glutathione transport & metabolism
Chair:  Lawrence H. Lash

Hepatic transport of glutathione: Mechanisms and relationship to liver function and pathology
  Ned Ballatori, Univ. of Rochester

Mitochondrial glutathione transport: role in susceptibility to chemically induced apoptosis
  Larry H. Lash, Wayne State Univ.

Regulation of glutathione synthesis: Disease models and health implications
  Terrance J. Kavanagh, Univ. of Washington

Transport of glutathione and glutathione conjugates by multidrug resistance proteins
  Susan P. Cole, Queen's Univ., Kingston, Ontario

Phospholipase C-ε: A multifunctional signaling protein regulated by both heterotrimeric & Ras superfamily G proteins
Chair: T. Kendall Harden

Mechanisms of receptor-mediated regulation of PLC-epsilon
  Grant G. Kelley, SUNY Upstate Med. Univ., Syracuse

Regulation of PLC-epsilon by G alpha subunits
  Jon W. Lomasney, Northwestern Univ.

Rho-mediated activation of PLC-epsilon
  Michele R. Wing, Univ. of North Carolina, Chapel Hill

Function of PLC-epsilon in cardiac function and carcinogenesis
  Tohru Kataoka, Kobe Univ., Japan

Sunday Afternoon (3:00 pm - 5:30 pm)

Emerging concepts & compounds in obesity therapeutics
Chairs:  Terry J. Opgenorth & Lou A. Tartaglia

The FDA obesity guidance
   Patricia Beaston, FDA

Unraveling the central nervous system pathways regulating body weight homeostasis
  Joel K. Elmquist, Harvard Med. Sch.

Hypothalamic regulation of insulin action
  Luciano Rossetti, Albert Einstein Col. of Med.

Development of selective thyroid hormone receptor agonists for treatment of obesity and hyperlipidemia
  Johan Malm, Karo Bio AB, Huddinge, Sweden

Endocannabinoids and energy balance: CB-1 receptor antagonists for the treatment of obesity
  Andy G. Swick, Pfizer, Inc.

Trans-3,4-dimethyl-4-arylpiperidine opioid receptor antagonists as a novel treatment for obesity
 M.A. Statnick, Eli Lilly and Co.

MC4 receptor as a potential target for the treatment of obesity.
  Tung M. Fong, Merck and Co.

APD 356, a novel 5-HT_2c agonist for the treatment of obesity
  C. Bjenning, Arena Pharmaceuticals

Future directions in pharmacology graduate training
Chair:  Peter C. Preusch

Introduction: Training programs in pharmacology from the NIH perspective
  Peter C. Preusch, NIH, NIGMS

What constitutes a good training program in pharmacology from the reviewer’s perspective
  James C. Garrison, Univ. of Virginia Sch. of Med.

What the pharmaceutical industry of the 21^st century is looking for in a pharmacologist
  Robert R. Ruffolo, Wyeth Res.

Reflections on the preparation of pharmacology faculty
  Suzanne B. Bausch, Uniformed Services Univ. of the Hlth. Sci.
  Karen M. Lounsbury, Univ. of Vermont

Reflections on preparation for industrial pharmacology
  Dolly A. Parasrampuria, McNeil Consumer & Specialty Pharmaceut.

New insights on calcium signaling & vascular function
Chair:  Joseph E. Brayden

The role for calcium in coordination of oscillating vascular smooth muscle cells
  Christian Aalkjaer, Univ. of Aarhus, Aarhus, Denmark

Encoding of calcium signals for vascular function
  Mark T. Nelson, Univ. of Vermont Col. of Med.

Assessments of smooth muscle calcium regulation using genetic and molecular approaches
  Michael I. Kotlikoff, Cornell Univ.

Regulation of vascular tone by transient receptor potential channels
  Joseph E. Brayden, Univ. of Vermont Col. of Med.

Neuroimaging: Strategies for application to preclinical neurotoxicology & neuropharmacology
Chair:  William Slikker

Neuroimaging as a new approach to preclinical neurotoxicology and neuropharmacology
  Bill Slikker, Jr., FDA, Natl. Ctr. for Toxicol. Res., Jefferson, Arkansas

Small animal imaging using positron emission tomography
  Arion Chatziioannou, UCLA Sch. of Med.

Investigating brain damage and repair with PET in rodents
  Harley Kornblum., UCLA

Brain T1 magnetic resonance imaging (MRI) is a semi-quantitative estimator of brain manganese concentrations in nonhuman primates (abstract 7436)
  David C. Dorman, CIIT Ctrs. For Hlth. Res., Research Triangle Park, NC

MRS to assess developmental neurotoxicity
  Christine C. Cloak, Brookhaven Natl. Lab

Pharmacology of ADHD in 2004
Chairs:  Monique Ernst & Jonathan L. Katz

The future of genetics in the pharmacology of ADHD
  James Kennedy, Ctr for Addiction & Mental Health, Univ. of Toronto

New therapeutic targets and animal models of ADHD
  Jerry J. Buccafusco, Med. Col.of Georgia

Novel treatment of ADHD
  Lawrence Greenhill, Columbia Univ.

Stimulant effects in the developing brain
  Susan Andersen, Harvard Med. Sch.

Functional neuroimaging in ADHD
  Monique Ernst, NIH NIMH/MAP

Monday Morning (9:30 am - 12:00 noon)

Therapeutic opportunities for histamine H₃ receptor ligands
 Chair:  Arthur A. Hancock         

Molecular pharmacology of the histamine H₃ receptor
   Rob Leurs, Vrije Univ., Amsterdam, The Netherlands

Effects of H₃ antagonists in a variety of animal models of learning, memory and attention, and the side-effect liabilities of such compounds
  Gerard B. Fox, Abbott Labs

Effects of novel histamine H3 receptor antagonists on food intake and body weight in rodents and in larger species
  Karin Rimvall, Novo-Nordisc A/S

Role of presynaptic H₃ receptors in myocardial ischemic states
  Roberto Levi, Cornell Univ.

Novel compounds interacting with the histaminergic system have antinociceptive effects in animal models
  Lindsay B. Hough, Albany Med. Col.

Advances in fluorescence methods for receptor studies: 3^rd International Symposium
Chair:  Ian McGrath    

Fluorescence in pharmacology
  Ian McGrath, Univ. of Glasgow

The use of fluorescent ligands in the study of vascular function
  Craig Daly, Univ. of Glasgow

Imaging neurotransmission at the nerve muscle junction
  Tom Cunnane, Univ. of Oxford

Kinetics of uptake and localization of fluorescent phorbol ester and protein kinase C or RasGRP3 as a function of time after phorbol ester addition. (abstract 3939)
  Derek C. Braun, NCI, NIH

Control of Ca⁺⁺ in the vascular wall
  Christian Aalkjaer, Univ. of Aarhus, Aarhus, Denmark

Use of fluorescent probes to study ligand-induced conformational changes in receptors
  Brian Kobilka, Stanford Univ.

Knockout mouse models for studying in vivo function of cytochrome P450 & other drug metabolizing enzymes
Chair: Xinxin Ding          

Using knockout and humanized mice to understand mechanisms of polycyclic hydrocarbon toxicity
  Tim Dalton, Univ. of Cincinnati

The role of CYP1B1 in the disruption of bone marrow hematopoiesis by polycyclic hydrocarbons
  Colin R. Jefcoate, Univ. of Wisconsin at Madison

Functional consequences of microsomal NADPH-cytochrome P450 oxidoreductase deficiency
  Anna Shen, Univ. of Wisconsin at Madison

A conditional P450 reductase knockout mouse model for investigating tissue-selective, P450-mediated drug metabolism and xenobiotic toxicity
  Xinxin Ding, New York State Dept. of Hlth.

Microarray Analysis of Hepatic Gene Expression in Liver-Specific NADPH-Cytochrome P450 Reductase Cpr-Knockout and Global Cpr-Knockdown Mouse Models (Abstract 4399)
  Yan Weng, SUNY at Albany

Targeting chemokine receptors in the central nervous system
 Chair: Jeffrey K. Harrison        

Diverse functions of chemokines in the CNS
   Jeffrey K. Harrison, Univ. of Florida

Modified virally encoded chemokines to probe structure-function of chemokine receptors
  Christopher N. Davis, Univ. of Florida Hlth. Sci. Ctr.

Chemokine regulation of lymphocyte and dendritic cell trafficking in experimental autoimmune encephalomyelitis
William J. Karpus, Northwestern Univ.

A genetic approach to understanding roles of chemokines and their receptors in animal models
  Richard M. Ransohoff, Cleveland Clinic Fndn.

Development and evaluation of small molecule chemokine receptor antagonists
  Richard Horuk, Berlex Biosciences

Tuesday Morning (9:30 am - 12:00 noon)

Polymorphisms in signaling cascades & effector molecules
Chair: J. David Port          

Polymorphisms in α- and β-ARs; relationship to outcomes in cardiovascular disease
  Stephen B. Liggett, Univ. of Cincinnati

Genomic and posttranscriptional regulation of serotonin 5-HT2 receptor signaling
  Elaine Sanders-Bush, Vanderbilt Univ.

Functional consequences of ion channel gene variants: Relationship to inherited arrhythmias
  Robert S. Kass, Columbia Univ.

Polymorphisms in neurotransmitter transporters: Impact on transporter structure, function and regulation
  Randy D. Blakely, Vanderbilt Univ.

Frontiers in anticoagulant pharmacology: New insights on mechanism of action & emerging novel therapeutics
Chairs: Madhu S. Chintala & Giora Z. Feuerstein

New insights into mechanisms of initiation and propagation of the coagulation cascade
  Dougald Monroe, Univ. North Carolina at Chapel Hill

Thrombin receptor antagonists (PAR-1) as a novel approach in antiplatelet therapeutics
  Madhu S. Chintala, Schering-Plough Res. Inst.

Future anti-coagulants: Is 9 the winning number?
   Giora Z. Feuerstein, Merck Res. Labs

Importance of animal models in thrombosis – research in guiding translation medicine
   Ben R. Lucchesi, Univ. of Michigan Med. Sch.

          
Early ADME support & the drug discovery process
Chair:  Adedayo Adedoyin          

Impact of high throughput assays on drug discovery
  Adedayo Adedoyin, Aventis Pharmaceut.

Permeability assays on drug discovery
  Tycho Heimbach, Pfizer Global R&D

Assessment of metabolic stability in drug discovery
  Michael Sinz, Bristol-Myers Squibb

High throughput CYP inhibition assays
Larry Wienkers, Pharmacia

Gender and the pharmacology of eating disorders:  Linking molecules and signals to behavior
 Chair:  Joan M. Lakoski
 Speakers:

Estrogen regulation of pituitary leptin
   Gwen V. Childs, Univ. of Arkansas for Med. Sci.

On being female: A neuroanatomical perspective of neuropeptide Y receptor and estrogen interactions
   Janice H. Urban, Finch Univ./Chicago Med. Sch.

Sex hormones, body weight regulation and food intake
   Deborah J. Clegg, Univ. of Cincinnati Sch. of Med.

Gender and dietary nutrient regulation of insulin action
   Renee Commerford, Novartis Inst. for Biomedical Res.

A rat model of binge-type eating: What we have learned so far
   Rebecca L. Corwin, Penn State Univ.

Short Course: A beginner's guide to RNAi
Chair: Michael T. McManus

Biology of RNA interference in mammals
  Michael T. McManus, MIT

How to use siRNAs
  Gyorgy Hutvagner, Univ. of Massachusetts Med. Sch.

How to make and use pol III hairpins
  Dave Turner, Univ. of Michigan.

How to make and package lentiviral RNAi vectors
  Luk Van Parijs, MIT

Web Resources for this course

Tuesday Afternoon (3:00 pm - 5:30 pm)

siRNAs:  Research tools/therapeutic molecules?
Chair:  Michael McManus   

Mechanisms of action of siRNAs
Gyorgy Hutvagner, Univ. of Massachusetts Med. Sch.

Mechanistics aspects of rational siRNA design
  Anastasia Khvorova, Dharmacon

Hairpin-delivered siRNAs in cell culture
  Dave Turner, Univ. of Mich.

Lentiviral RNAi vectors for the identification and validation of novel therapeutic targets
  Peter Sandy, MIT

SiRNAs – transition to therapeutic molecules in humans
   Jolanta Vidugiriene, Promega

Wednesday Morning (9:30 am - 12:00 noon)

Dopamine receptor blockade in the development of 'atypical' antipsychotic agents
Chair:  Jack Bergman & Joseph Wettstein         

The continued utility of dopamine receptor blockers in the treatment of psychosis
  Philip G. Janicak, Univ. of Illinois at Chicago

Dopamine partial agonists as dopamine receptor stabilizers: The next generation of dopamine-based antipsychotic drugs
  Nicholas Waters, Carlsson Res. AB, Göteborg, Sweden

Dissociation rate from D₂ receptors as a predictor of “atypicality” in antipsychotic action
  Philip Seeman, Univ. of Toronto

The role of 5HT_1A receptor activity in behavioral effects of some “atypical” antipsychotics
  Wouter Koek, Univ of Texas Hlth. Sci. Ctr. at San Antonio

Preclinical identification of serotonergic and glutametergic targets for the development of novel antipsychotics
  Mark A. Geyer, UCSD Sch. of Med.

Protein-protein interactions in cellular signaling cascades: A new frontier for drug discovery
Chair: Haian Fu     

Keynote lecture:  Drug discovery at signaling interfaces
  James A. Wells, Sunesis Pharmaceut., Inc., San Francisco

 

Dynamic visualization of biochemical networks in living cells
   Stephen Michnick, Univ. of Montreal

 

Targeting phosphorylation-dependent protein-protein interactions
  Haian Fu, Emory Univ. Sch. of Med.

 

Small molecule modulation affecting G-protein signaling: A unique approach to the GPCR pathway
  Kathleen H. Young, Wyeth Research

Phosphodiesterases -- Status as therapeutic targets

Chair:  James Winkler

A series of sub-nanomolar PDE5 inhibitors leading to a clinical candidate more potent and selective than sildenafil
  John E. Macor, Bristol Myers Squibb

Discovery and development of PDE4 inhibitors
  Tim Martins, ICOS Corp.

Discovery and development of cGMP PDE inhibitors
  Joe Thompson, OSI Pharmaceut.

Phosphodiesterase 3 – status as a therapeutic target
  Vincent C. Manganiello, NHLBI, NIH

Neuroprotective effects of natural products
Chairs:  Nancy Pearson and Dale Birkle

Mitochondrial dysfunction and therapies in Parkinson’s disease
  Clifford W. Shults, UCSD

Creatine as a neuroprotective treatment in Huntington’s disease: Preclinical and early clinical studies
  Steven M. Hersch, Harvard Med. School

The multiplicity of actions of fruit polyphenolics in forestalling and reversing the deleterious effects of brain aging and behavior
    James A. Joseph, Tufts Univ.

Use of Ginkgo biloba in dementia and Alzheimer’s disease: The Gingko in Evaluation of Memory (GEM) dementia prevention trial
   Steven T. DeKosky, Univ. of Pittsburgh

Drug Metabolism Platform Session and James Gillette Best Manuscript Awards
   Chairs: Michael R. Franklin and Tim S. Tracy

Wednesday Afternoon (3:00 pm - 5:30 pm)

Nexuses between dopamine & serotonin systems:  Implications for antipsychotic drug actions 
Chair:  Frank I. Tarazi and John A. Schetz

Selective dopamine/serotonin receptors mediate actions of antipsychotic drugs
  Frank Tarazi, Harvard Med. Sch.

Mechanism of actions of atypical antipsychotic drugs: Role of serotonin 5-HT1A agonism
  Junji Ichikawa, Vanderbilt Univ. Sch. of Med.

Molecular interaction sites for therapeutic agents targeting dopamine and serotonin receptors
  John Schetz, Univ. of North Texas Hlth. Sci. Ctr.

Neurophysiological effects of antipsychotics on dopamine and serotonin systems
  Kurt Rasmussen, Eli Lilly and Co.

Rescuing mutant receptors & proteins:  A new drug development strategy
 Chair:  P. Michael Conn        

Influence of molecular and chemical chaperones on protein folding
  William J. Welch, UCSF

Rescue of mutants of the human gonadotropin releasing hormone receptor: Therapeutic strategies
  P. Michael Conn, Oregon Hlth and Sci. Univ.

Pharmacological chaperones acting on the V2 receptor; potential therapeutic applications
  Michel Bouvier, Univ. of Montreal

Retention of an aggregated mutant protein in the ER causes liver disease: Mechanisms of injury and potential chemoprophylactic strategies
  David H. Perlmutter, Univ. of Pittsburgh Sch. of Med. and Children's Hosp. of Pittsburgh

Environmental agents & ion channel function
Chairs:  William D. Atchison & Timothy Shafer         

Disruption of cerebellar GABA_A receptor-mediated inhibition by environmental mercurials, a possible contributor to selective neuronal vulnerability
  William D. Atchison, Michigan State Univ.

Disruption of function of high-voltage activated calcium channels by environmental agents – implications for developmental function
  Timothy Shafer, EPA, Research Triangle Park, NC

Site-specific actions of ethanol on NMDA receptors
  John J. Woodward, Med. Univ. of South Carolina

Impairment of LTP and spatial learning are associated with disruption in glutamatergic synaptic function produced by environmental type exposure to lead
  Tomas R. Guilarte, Johns Hopkins Univ.

Modulation of ligand-gated chloride channels in insect and mammalian neurons
  Xilong Zhao, Northwestern Univ.

Inhibition of neuronal nicotinic acetylcholine receptors by the abused solvent, toluene
  Ambuja Bale, EPA, Research Triangle Park, NC.

Cancer chemotherapy & drug metabolism
 Chair: David S. Riddick         

Interactions of anthracyclines with drug-metabolizing enzymes
  David S. Riddick, Univ. of Toronto

Bioreductive pro-drugs: Routes of activation and potential application in gene therapy
  Ian J. Stratford, Univ. of Manchester

Cytochrome P450-based cancer gene therapy
  David J. Waxman, Boston Univ.

Role of glutathione conjugation and efflux in cellular resistance to alkylating agents and other reactive electrophiles
  Charles S. Morrow, Wake Forest Univ.

Division Sessions (to date)

Monday Morning (9:30 am - 12:00 noon)

Division for Pharmacology Education Workshop:
    Team learning:  Small-group activities in the large-group lecture hall
     Moderators:  Kathryn K. McMahon and Charles L. Seidel

Lectures remain the main instructional modality because they are efficient and summarize large bodies of material.  However, learners are passive recipients of information.  To increase active learning, small-groups have been adopted.  This allows problem solving and application of knowledge in real-life situations but, demands faculty and facilities and can result in uneven inter-group instruction.  Team Learning (TL) combines the strengths of lectures and small-groups.  TL consists of three phases. In Phase 1learners acquire required content through self-study, lectures or both.  In Phase 2 learners demonstrate their readiness to apply information through tests taken individually and in small-groups followed immediately by faculty feedback.  In Phase 3 students solve problems in small-groups in the lecture hall.  Keys to this phase are that groups work on the same problem, select their solution from a list, and simultaneously declare their selection.  Problems are designed to generate inter-group controversy which faculty exploit as groups orally defend their selections.  The rich discussion enables faculty to correct student thinking and model critical thinking. 

This two-hour workshop will expose participants to the principles of Team Learning through their participation in a mock course using Team Learning.  At key intervals participants will reflect on specific Team Learning principles to learn more about the process and to appreciate how Team Learning may be applied to their specific circumstance.  By the end of the workshop participants will be able to describe the three phases of Team Learning, define differences between Readiness Assurance Tests and Group Activity questions and describe the elements of a good Group Activity question. 

This session is free but there is limited space.  Please sign up for this session by sending an email to Nancy White in the ASPET Meetings Department at nwhite@aspet.org.

Monday Afternoon (3:00 pm - 5:30 pm)

Division for Drug Discovery, Drug Development & Regulatory Affairs Symposium:
     Drug discovery & development:  From idea to approval
     Chair:  Benjamin Yerxa     

Drug discovery: Finding new targets and active compounds
   H. Jefferson Leighton, BioDesign, Boston, MA

Drug evaluation: Non-clinical investigations of drug candidates
   Ben Yerxa, Inspire Pharmaceut.

Drug development: Establishing clinical human safety and efficacy
   Karla Jacobus, PPD Develop., Morrisville, NC

Drug approval: The FDA and the regulatory process
   Pauliana Hall, PCH Integrated Regulatory Services, Laguna Niguel, CA
 

Division for Behavioral Pharmacology Workshop:
     Quantitative methods in behavioral pharmacology
     Moderator:  Jonathan L. Katz
     Introduction. Jonathan L. Katz, NIDA, NIH, IRP    

     The isobole field and its application to quantitating opioid agonist interactions.
       Ronald J. Tallarida, Temple Univ. School of Medicine

     Milligrams and isobolograms: Assessing drug intereactions in behavioral pharmacology
       Stephen G. Holtzman, Emory Univ.

     Opioid agonist interactions in rhesus monkeys: A case study in the of dose-addition
     analysis and the evaluation of drug combinations
       S. Stevens Negus, Harvard Med. Sch.

     Self-administration of drug mixtures
       W.L. Woolverton, Univ. of Mississippi Med. Ctr.

Division for Cardiovascular Pharmacology Graduate Student and Postdoctoral
 Scientist Best Paper Competition
  Chairs: Steven P. Jones and Richard H. Kennedy

Division for Molecular Pharmacology Postdoctoral Awards Finalists
  Chair: Palmer W. Taylor
  A new approach to structure-guided drug design: Fluctuations in the drug target and freeze frame inhibition
    Palmer W. Taylor, UCSD
 

Tuesday Afternoon (3:00 pm - 5:30 pm)

Division for Neuropharmacology Symposium:
     Cell biology of the catecholamine neuron:  A symposium in honor of Julius Axelrod celebrating a decade of
      molecular exploration of mammalian phenotypes of catecholamine biosynthetic enzyme, transporter and metabolizing enzyme deficiencies,
      and their clinical relevance to neuronal excitability, food- and drug-related behaviors, and neuronal development and degeneration.
     Chair:  Lee Eiden

         Introduction
           Solomon Snyder, Johns Hopkins Univ.

         Disruption of striatal dopamine signaling causes amphetamine-induced hypophagia
            Richard Palmiter, Univ. of Washington.

         The vesicular monoamine transporters and other regulated traits of monoamine-secreting cells
             Lee Eiden, NIMH-IRP, NIH

          Regulated trafficking of catecholamine transporters in presynaptic terminals

            Randy D. Blakely, Vanderbilt Univ.

          COMT: From gene to brain and behavior

             Daniel Weinberger, NIHM-IRP, NIH

Division for Systems and Integrative Pharmacology Symposium:
     Calcium mobilization to calcium sensitization:  Identifying new pharmacologic targets in smooth muscle
      Chairs:  George Christ & Chris Wingard    

Regulation of Ca²⁺- mobilization in detrusor muscle
  Gerry Herra, Univ. of Vermont College of Medicine

 

K⁺ channels, gap junctions and smooth muscle
  George J. Christ, Albert Einstein College of Medicine

 

Actin cytoskeletal remodeling in smooth muscle
  William T. Gerthoffer, Univ. of Nevada School of Medicine

 

ROS and Ca²⁺-sensitivity in smooth muscle
  Keith A. Jones, Mayo Clinic

 

EETs and ionic conductance systems in cerebral vascular muscle
  David R. Harder, Medical College of Wisconsin

 

Rho-kinase and PKC sensitization in cavernosal smooth muscle

  Chris J. Wingard, Medical College of Georgia

Division for Clinical Pharmacology Symposium: Mechanisms of gender
effects on human drug response
  Chair: David A. Flockhart
         Mechanisms of gender effects on pharmacodynamics: Ion channel activity
           Steven N. Ebert, Georgetown Univ. Med. Ctr.

         Mechanisms of gender effects on pharmacokinetics
            J. Christopher Gorski, Indiana Univ. Sch. of Med.

         Mechanisms of gender effects on disease: Gender differences in 'intermediate phenotypes' for hypertension
             Daniel T. O'Connor, UCSD
 

Division for Toxicology Symposium: Hepatoxicity: Signaling mechanisms in cell death and survival
  Chair: Harihara M. Mehendale

Mechanisms of acetaminophen hepatotoxicity: Oxidant stress and regeneration
  Hartmut Jaeschke, Univ. of Arizona

Inflammation: A susceptibility factor in drug-induced liver injury
  Robert A. Roth, Michigan State Univ.

Survival mechanisms in fatty hepatocytes
  Anna Mae Diehl, Johns Hopkins Univ.

Mechanisms of progression and regression in liver injury
  Harihara M. Mehendale, Univ. of Louisiana at Monroe

Special Sessions

Friday and Saturday

Behavioral Pharmacology Society Meeting (6:00pm Friday - 7:00pm Saturday)

For program and registration information, contact Alice Young

Saturday Afternoon (1:00 pm - 6:30 pm)

Graduate Student Colloquium
Preserving and promoting our discipline: A workshop emphasizing pharmacology student participation

Chairs: Myron L. Toews, Stephanie W. Watts,  and Barbara S. Beckman
1:00 pm - 3:00 pm

Pharmacology is a basic science discipline that encompasses a wide range of scientific interests, yet possesses the unique focus of studying substances that interact with living systems through chemical processes.  As a discipline, pharmacology does not have the profile possessed by others, including physiology, microbiology and immunology.  The focus of this workshop will be to utilize the talent and thought of our graduate students, in combination with Graduate Directors from across the nation, and address questions/issues critical to preserving and, importantly, promoting pharmacology.  Small groups will break out with a charged topic and, near the end of the meeting, present their ideas to the group.  Where appropriate, these items will be forward to Council of ASPET for discussion.

Possible topics:

Summer Undergraduate Programs - does your institution have one? Is it useful in recruiting students to pharmacology?

Undergraduate Pharmacology courses - does your institution have one? Is it useful in recruiting students to pharmacology?

Incorporating pharmacology into other undergraduate courses (Physiology, micro)
Recruiting graduate students:
What works?
What DOESN'T work?

Getting our message and identity out to the world (what is our message and how do we relay it?)***
I CONSIDER ISSUE 5 EXTREMELY CRITICAL.  We suffer from an amazing lack of PR or understanding, but yet every individual in a developed country is living a life improved because of pharmacology.  How do we make the public at large understand how important this is to their lives, and how proper training of students is necessary to ensure continuing development of drugs for future generations? 

How is pharmacology "better" and/or "different" than other disciplines?  How did you find out about pharmacology?

How can graduate students be proactive in their departments and schools?

How can graduate students be proactive at a higher level?

What are resources and affiliations available to pharmacology Graduate students?

Would interaction with industry in a formal way be of use to your education as a pharmacologist?  If so, how do you envision this?

Pharmacology Graduate Program Directors Meeting
3:00 pm - 4:30 pm

2004 Teaching Institute
Strategies for collaborative/integrative teaching & research relationships between pharmaceutical sciences and pharmacy practice faculties
 Chairs:  Ed Bilsky & Paula Witt-Enderby     

 4:30 pm - 6:30 pm     

Pharmacy education: Building a strong foundation for practice through science and research
  Gayle A. Brazeau, SUNY at Buffalo

Impact of clinical research on patient care
  Milap C. Nahata, Ohio State Univ. Col. of Pharmacy

Coordinated PharmD and PhD programs: Building ridges from the bench to the clinic
  Kim L. R. Brouwer, Univ. of North Carolina at Chapel Hill

Sunday Morning (8:30 am - 12:00 pm)

Minorities Committee Symposium
Careers in Science:  The specifics of how to get where you want to be
Chairs: Richard De La Garza and Margarita L. Dubocovich

The Minorities Committee: Current goals and future objectives
  Margarita L. Dubocovich, Northwestern Univ.

An overview of career paths in science
  Richard De La Garza, II, Albert Einstein Col. of Med.

A career in academia
  Sunny Ohia, Univ. of Houston

A career in industry
  Marlene L. Cohen, Creative Pharmacology Solutions LLC

A career in government science
  Jean Lud Cadet, NIH, NIDA, IRP, Baltimore

A career as a college professor
  Shubhik K. DebBurman, Lake Forest Col.

A career in science editing
  Barbara B. Van Renterghem, Eaton Publishing

Monday Afternoon (12:30 pm - 2:00 pm)

Public Affairs Workshop
Scientific & regulatory challenges involving dietary supplements & botanical products
 Chair:  Rudolph Juliano       

Speakers:

Lester Crawford, Acting Commissioner, Food and Drug Administration

Paul M. Coates, Director, Office of Dietary Supplements, NIH

Stephen E. Straus, Director, National Center for Complementary and Alternative Medicine, NIH

 

Topics to be addressed include: how to promote a stronger scientific foundation at the FDA and the need to promote better health through better research; how new collaborations with NIH will help to improve our understanding of the underlying mechanisms of action and help to improve safety and efficacy of these products; research opportunities for the extramural community; and regulatory perspectives on the Dietary Supplement Health & Education Act of 1994 (DSHEA).

Tuesday Morning (9:30 am - 12:00 pm)

Short Course
A beginner's guide to RNAi
Chair: Michael T. McManus

Biology of RNA interference in mammals
  Michael T. McManus, MIT

How to use siRNAs
  Gyorgy Hutvagner, Univ. of Massachusetts Med. Sch.

How to make and use pol III hairpins
  Dave Turner, Univ. of Michigan.

How to make and package lentiviral RNAi vectors
  Peter Sandy, MIT

Tuesday Afternoon (12:30 pm - 2:00 pm)

Public Affairs Workshop
Sustaining integrative & organ systems sciences:  Problems, opportunities, solutions
Co-sponsored by the American Association of Anatomists, American Physiological Society, and American
Society for Nutritional Sciences

  Chair:  David B. Bylund

Jerry J. Buccafusco, Medical College of Georgia
Peter Preusch,  NIGMS, NIH
Gerald Schaefer, Wil Research Laboratories, Inc.
Stanley J. Wiegand, Regeneron PHarmaceuticals

Steve Zeisel, Univ. North Carolina
Irv Zucker, Univ. Nebraska
 

The advent of molecular biology has produced a vast wealth of information on human health and disease. However, there has been a diminishment in the number and ability of trained investigators – and students pursuing training and research – in the integrative and organ systems sciences. Science cannot effectively study disease or treatments for a disease simply by using isolated molecules, cells, or organs. Speakers will give their perspectives on the challenges and opportunities for enhancing the integrative & organ systems sciences by addressing its impact on both academic and industrial concerns.

Lectures 

John V. Croker Lecture - Sir James W. Black, James Black Foundation, London, UK
 Monday,  8:15 am - 9:15 am
"A Biography of Gastrin"

P.B. Dews Award Lecture - Joseph V. Brady, Johns Hopkins University
Monday, 1:45 pm - 2:45 pm
"The origin and development of behavioral pharmacology"

Bernard B. Brodie Award Lecture - Thomas L. Poulos, University of California, Irvine
Monday, 1:45 pm - 2:45 pm
"Structural and functional diversity in heme monoxygenases"

General Information

Awards

Call for Abstracts

Hotels

Registration